Hematological oncology | Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research at UCSF

THERAPY-DRIVEN EVOLUTION AND INTRATUMORAL GENETIC HETEROGENEITY IN CNS LYMPHOMAS.

Hematological oncology

D. A. Solomon, H. Geng, M. Randall, R. Sobel, J. Cleveland, A. Ballapuram, L. Chen, M. Lu, S. Cha, C. Lowell, W. P. Devine, J. L. Rubenstein

CHECKMATE 647: A PHASE 2, OPEN-LABEL STUDY OF NIVOLUMAB IN RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA OR RELAPSED/REFRACTORY PRIMARY TESTICULAR LYMPHOMA.

Hematological oncology

L. Nayak, F.M. Iwamoto, A.J. Ferreri, A. Santoro, S. Singer, C. Batlevi, T. Batchelor, J. Rubenstein, P. Johnston, R. Ramchandren, C. Soussain, J. Drappatz, K. Becker, M. Witzens-Harig, G. Illerhaus, A. Herrera, A. Masood, M. Shipp

Preliminary analysis of lenalidomide maintenance after methotrexate-temozolomide-rituximab induction in older patients with PCNSL.

Hematological oncology

J.L. Rubenstein, J. Hwang, G. Mannis

On point in primary CNS lymphoma.

Hematological oncology

Tsang M, Cleveland J, Rubenstein JL

IDENTIFICATION OF GENOMIC BIOMARKERS OF DISEASE PROGRESSION AND SURVIVAL IN NEWLY-DIAGNOSED PRIMARY CNS LYMPHOMA.

Hematological oncology

S. Mo, H. Geng, A. Ballapuram, L. Chen, M. Lu, W. P. Devine, K. W. Wen, D. Solomon, J. Rubenstein

BTK Degradation as a Novel Therapeutic Strategy in Relapsed CNS Lymphoma: Proof of Concept Studies in Intracranial Preclinical including Patient-Derived Models.

Hematological oncology

J. Ma, M. Lu, L. Chen, H. Geng, A. Kumar, M. Noviski, R. Rountree, C. Guiducci, J. Rubenstein

THE TOLL-LIKE RECEPTOR 7/8 PATHWAY HAS PROGNOSTIC SIGNIFICANCE AND IS A THERAPEUTIC TARGET IN CNS LYMPHOMAS.

Hematological oncology

H. Geng, M. Randall, A. Ballapuram, L. Chen, C. Yung, M. Lu, C. Lowell, J. L. Rubenstein

Subscribe to Hematological oncology